| Literature DB >> 32247292 |
Ulrike Leiter1, Markus V Heppt2,3, Theresa Steeb2,3, Teresa Amaral1, Andrea Bauer4, Jürgen C Becker5, Eckhardt Breitbart6, Helmut Breuninger1, Thomas Diepgen7, Thomas Dirschka8, Thomas Eigentler1, Michael Flaig2, Markus Follmann9, Klaus Fritz10, Rüdiger Greinert6, Ralf Gutzmer11, Uwe Hillen12, Stephan Ihrler13, Swen Malte John14, Oliver Kölbl15, Klaus Kraywinkel16, Christoph Löser17, Dorothee Nashan18, Seema Noor1, Monika Nothacker19, Christina Pfannenberg20, Carmen Salavastru10, Lutz Schmitz21, Eggert Stockfleth21, Rolf-Markus Szeimies22, Claas Ulrich23, Julia Welzel24, Kai Wermker25, Claus Garbe1, Carola Berking2,3.
Abstract
Actinic keratoses (AKs) are common lesions in light-skinned individuals that can potentially progress to cutaneous squamous cell carcinoma (cSCC). Both conditions may be associated with significant morbidity and constitute a major disease burden, especially among the elderly. To establish an evidence-based framework for clinical decision making, the guidelines for actinic keratosis and cutaneous squamous cell carcinoma were developed using the highest level of methodology (S3) according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF). The guidelines are aimed at dermatologists, general practitioners, ENT specialists, surgeons, oncologists, radiologists and radiation oncologists in hospitals and office-based settings as well as other medical specialties involved in the diagnosis and treatment of patients with AKs and cSCC. The guidelines are also aimed at affected patients, their relatives, policy makers and insurance funds. In the second part, we will address aspects relating to epidemiology, etiology, surgical and systemic treatment of cSCC, follow-up and disease prevention, and discuss AKs and cSCC in the context of occupational disease regulations.Entities:
Mesh:
Year: 2020 PMID: 32247292 DOI: 10.1111/ddg.14072
Source DB: PubMed Journal: J Dtsch Dermatol Ges ISSN: 1610-0379 Impact factor: 5.584